Cyclopharm Limited · ASX:CYC
Cyclopharm — Shareholder Meeting (May 2015)
21 slides from Cyclopharm's shareholder meeting presentation, May 26, 2015
Slide 1: Cyclopharm Limited 2015 Annual General Meeting
For personal use only Cyclopharm Limited 2015 Annual General Meeting May 2015
Slide 2: Agenda
Agenda For personal use only Acting Chairman’s Address Managing Director’s Review Questions Formal Business 2
Slide 3: Acting Chairman's Address
For personal use only Acting Chairman’s Address DAVID HEANEY 3
Slide 4: Introduction
Introduction For personal use only World leading, high demand, patented nuclear medicine technologies Profitable and cash flow positive – growing on record FY14 results Multiple significant growth options being implemented now Strong balance sheet with capacity to fund ongoing R&D Market b
Slide 5: Cyclopharm: Our business lines
Cyclopharm Our business lines For personal use only Manufacturer and • Continues to generate growing distributor of lung ventilation revenue, profits and cash flows (Technegas) imaging drugs and equipment • Trials underway to extend usage to COPD treatment & monitoring • FDA trials progressing Techn
Slide 6: Managing Director's Review
For personal use only Managing Director’s Review JAMES MCBRAYER 6
Slide 7: FY14 Financial Highlights
FY14 Financial Highlights For personal use only Record sales of $12.1 million Record Technegas division operating EBITDA of $2.2 million Record NPAT of $4.1 million (vs 2013 loss of $10.1m), includes: Technegas division NPAT: $2.4 million; and Net litigation proceeds of $2.2 million Tech
Slide 8: FY14 Operating Highlights
FY14 Operating Highlights For personal use only Technegas’ sales revenue grew in all major markets Sales of Technegas Generators & Patient Administration Sets up 10% on pcp Canada now represents our no.1 market Commenced Technegas COPD trials in China Progress in obtaining FDA approval for
Slide 9: Group Profit & Loss
Group Profit & Loss For personal use only Record Sales and Profit Year ended 31 December ($000’s) 2014 2013 • Technegas continues to perform Underlying Results1: strongly Revenue 12,047 11,882 • Price increases and lower A$ drove improved gross margins Technegas EBITDA (Excludes FDA costs) 2,638 2,2
Slide 10: Group Balance Sheet
Group Balance Sheet For personal use only Balance Sheet strong with Major Debt Retired Year ended 31 December ($000’s) 2014 2013 • Improved cash position driven by strong cash flows from Cash 3,268 1,221 operations Other current assets 5,582 6,231 Non‐current Assets 2,111 1,067 • Net proceeds from C
Slide 11: Technegas – FY14 Performance
Technegas – FY14 Performance For personal use only Record financial result Year ended 31 December ($000’s) 2014 2013 Change • Technegas recorded a record Technegas Results1: financial result in FY14 Sales Revenue • PAS margins enhanced by PAS 9,384 8,583 ↑ 9.3% improved local prices in Asia and Gene
Slide 12: Technegas Sales Revenue
Technegas Sales Revenue For personal use only Consistent Organic Growth Patient Administration Sets (PAS) Technegas Sales Revenue • PAS revenue up 9.3% from 2013 $2.11m • PAS volumes down 1.7% from 2013 $1.87m $2.10m Technegas Generators • Generator revenue up 12.4% $8.58m $9.38m from 2013 $7.27m •
Slide 13: Technegas: Expanding the global footprint
Technegas Expanding the global footprint For personal use only • Technegas sold in 55 countries Technegas Sales Revenue by Region − In 2014 Canada became largest single market for Technegas Asia Pacific • Over 3,000,000 patient studies since 1986 Europe 19% & Other North • 1,350 Technegas generators
Slide 14: Technegas New Indications – COPD
Technegas New Indications – COPD For personal use only • Cyclopharm is undertaking a trial in China to assess the use of Technegas for the management of Chronic Obstructive Pulmonary Disease (COPD) − 200 patient trial expected to conclude in late 2015 • Expanding the use of Technegas from Pulmonary
Slide 15: Ultralute
UltraluteTM For personal use only • Cyclopharm patented technology • Extends the effective life of Mo‐99 generator up to 50% • Global interest continues to grow • Patent secured in 2014 • First sales anticipated in late 2015 • Market introduction represents a base platform for additional application
Slide 16: PET
For personal use only PET • Joint venture with: X‐Ray • 50% Alfred Health Solutions CT • 30% Macquarie University • 20% Cyclopharm • Comprehensive suite of imaging modalities Cardiac CT • State of the art research platform MRI • Growth and profitability linked to ramp‐up of Macquarie University Hosp
Slide 17: Summary and Outlook
Summary and Outlook For personal use only Solid growth prospects and healthy capital position Record financial results in 2014 Underlying profitability up significantly due to sales and margin expansion Technegas organic revenue and earnings growth to continue, driven by: Emergence of Canada
Slide 18: 2015 AGM Questions
For personal use only 2015 AGM QUESTIONS 18
Slide 19: 2015 AGM Formal Business
For personal use only 2015 AGM FORMAL BUSINESS 19
Slide 20: Proxy Summary
Proxy Summary For personal use only Resolution Business For* Against Abstain Proxy’s discretion 1 Remuneration Report 31,662,895 10,984,944 - - 2 Re-election of Mr David 42,640,294 - 7,545 - Heaney 3 Renewal of share buy- 31,639,875 11,002,534 5,430 - back capacity 4 Issue of LTIP shares to 42,565,2
Slide 21: Disclaimer
Disclaimer For personal use only Certain views expressed here contain information derived from publicly available sources that have not been independently verified. The presentation includes certain statements, estimates and projections with respect to the anticipated future financial performance of